Table 4: ATI Frequency Assayed by three Different Methods for all Studied Time Points.
|
[IFX] μg/mL at W6 |
bridging ELISA |
IDKmonitor |
ARIA |
| W2 |
IFX ≥4.4 n=44 |
0 |
0 |
0 |
| IFX <4.4 n=20 |
0 |
1 (5%) |
1 (5%) |
| p |
1 |
0.33 |
0.33 |
| W6 |
IFX ≥4.4 n=44 |
0 |
1 (2.3%) |
2 (4.5%) |
| IFX <4.4 n=20 |
4 (20%) |
7 (35%) |
10 (50%) |
| p |
0.007 |
0.002 |
0.001 |
| W14 |
IFX ≥4.4 n=44 |
2 (4.5%) |
7 (16%) |
12 (27.3%) |
| IFX <4.4 n=20 |
11 (55%) |
16 (80%) |
16 (80%) |
| p |
<0.0001 |
<0.0001 |
0.0006 |
| W22 |
IFX ≥4.4 n=44 |
5 (11.4%) |
20 (45.5%) |
25 (56.8%) |
| IFX <4.4 n=20 |
15 (75%) |
18 (90%) |
18 (90%) |
| p |
<0.0001 |
<0.0001 |
0.01 |
| W54 |
IFX ≥4.4 n=44 |
5 (11.4%) |
22(50%) |
27(61.3%) |
| IFX <4.4 n=20 |
15 (75%) |
18 (90%) |
18 (90%) |
| p |
<0.0001 |
0.002 |
0.02 |
ARIA, acid-dissociation radioimmunoassay (Sanquin, Amsterdam, The Netherlands); IDKmonitor, commercial kit (Immundiagnostik, Bensheim, Germany); IFX, infliximab; W, week.